Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Docs OK Hip, Knee Procedures For Outpatient Medicare Payment, But Change Could Cripple Bundling

Executive Summary

Many physicians commenting on a proposed change to the CMS Outpatient Prospective Payment to remove total and partial knee and hip arthroplasty procedures from the "inpatient procedures only" list favor the change. But some worry that the change could restrict care in some regions, in addition to adding challenges to bundled-payment models and leading to too many physician self-referrals.

You may also be interested in...



Could CMS Changes To Bundled Pay Models Stifle Medtechs' Value-Based Pay Plans?

The US Center for Medicare and Medicaid Services proposed downsizing its CJR joint replacement value-based payment model and outright canceling its cardiac procedure bundled payment model. Will the move discourage companies like Zimmer Biomet, Johnson & Johnson, and Medtronic, which have already invested in programs based on the value-based models?

Medicare Proposal To Cover Outpatient Knee, Hip Procedures Raises Patient Selection, Bundling Questions

Improvements in technology surrounding knee and hip replacements means a shorter recovery time for patients, but a recent US CMS proposal to take the procedures off the "inpatient procedure only" list means surgeons will have to carefully choose Medicare patients that are appropriate for the outpatient setting, and payment bundles could be affected.

FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations

Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.

Topics

UsernamePublicRestriction

Register

MT121470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel